Table 1.
Demographics and Clinical Characteristics of the Study Population at Baseline
| Characteristic | mRNA-1273 (Moderna) N = 215 | BNT162b2 (Pfizer-BioNTech) N = 215 | Total N = 430 |
|---|---|---|---|
| Median age (IQR) | 53 (43, 60) | 53 (43, 61) | 53 (43, 61) |
| Sex | |||
| Male | 161 (74.9%) | 165 (76.7%) | 326 (75.8%) |
| Female | 54 (25.1%) | 50 (23.3%) | 104 (24.2%) |
| Cohort | |||
| SHCS | 177 (82.3%) | 175 (81.4%) | 352 (81.9%) |
| STCS | 38 (17.7%) | 40 (18.6%) | 78 (18.1%) |
| Centers | |||
| University Hospital Basel | 77 (35.8%) | 81 (37.7%) | 158 (36.7%) |
| University Hospital Bern | 53 (24.7%) | 49 (22.8%) | 102 (23.7%) |
| University Hospital Zurich | 85 (39.5%) | 85 (39.5%) | 170 (39.5%) |
| History of cardiovascular disease or metabolic syndrome | |||
| Yes | 75/215 (34.9%) | 77/215 (35.8%) | 152/430 (35.3%) |
| No | 140/215 (65.1%) | 138/215 (64.2%) | 278/430 (64.7%) |
| CD4 cell count (cells/µL)a | |||
| <200 | 3/177 (1.7%) | 4/175 (2.3%) | 7/352 (2.0%) |
| 200–350 | 13/177 (7.3%) | 10/175 (5.7%) | 23/352 (6.5%) |
| 350–500 | 18/177 (10.2%) | 26/175 (14.9%) | 44/352 (12.5%) |
| >500 | 143/177 (80.8%) | 135/175 (77.1%) | 278/352 (79.0%) |
| Unsuppressed viral load (≥200 copies/mL)a | |||
| Yes | 7/177 (4.0%) | 13/175 (7.4%) | 20/352 (5.7%) |
| No | 170/177 (96.0%) | 162/175 (92.6%) | 332/352 (94.3%) |
| Transplanted organb | |||
| Lung transplant | 20/38 (52.6%) | 21/40 (52.5%) | 41/78 (52.6%) |
| Kidney transplant | 18/38 (47.4%) | 19/40 (47.5%) | 37/78 (47.4%) |
| Immunosuppressive therapyb | |||
| Less intense (<2 regimen) | 5/38 (13.2%) | 11/40 (27.5%) | 16/78 (20.5%) |
| Intense (3 or 4 regimen) | 33/38 (86.8%) | 29/40 (72.5%) | 62/78 (79.5%) |
| Antibody test to the nucleocapsid proteinc | |||
| Nonreactive | 197 (91.6%) | 181 (84.2%) | 378 (87.9%) |
| Reactive | 9 (4.2%) | 30 (14.0%) | 39 (9.1%) |
| Missing | 9 (4.2%) | 4 (1.9%) | 13 (3.0%) |
Abbreviations: IQR, interquartile range; SHCS, Swiss HIV Cohort Study; STCT, Swiss Transplant Cohort Study.
Only considering patients from the Swiss HIV Cohort Study.
Only considering patients from the Swiss Transplant Cohort Study.
Elecsys N test [14] reactive to nucleocapsid protein indicates previous contact to severe acute respiratory syndrome coronavirus 2.